Kiora Pharmaceuticals Inc...

AI Score

0

Unlock

3.18
-0.23 (-6.74%)
At close: Jan 14, 2025, 3:59 PM
3.25
2.20%
After-hours Jan 14, 2025, 06:18 PM EST
undefined%
Bid 3.25
Market Cap 9.54M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 1.05
PE Ratio (ttm) 3.03
Forward PE n/a
Analyst Buy
Ask 3.37
Volume 44,022
Avg. Volume (20D) 41,614
Open 3.46
Previous Close 3.41
Day's Range 3.10 - 3.46
52-Week Range 3.00 - 8.98
Beta undefined

About KPRX

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, a...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 13, 2015
Employees 12
Stock Exchange NASDAQ
Ticker Symbol KPRX

Analyst Forecast

According to 1 analyst ratings, the average rating for KPRX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 214.47% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Kiora Pharmaceuticals Inc. is scheduled to release its earnings on Mar 24, 2025, before market opens.
Analysts project revenue of $750.00K, reflecting a n/a YoY growth and earnings per share of -0.7, making a -143.75% decrease YoY.
9 months ago · Source
+14.41%
Kiora Pharmaceuticals shares are trading higher af... Unlock content with Pro Subscription
11 months ago · Source
+53.92%
Kiora Pharmaceuticals shares are trading higher after the company announced a private placement of up to roughly $45 million.